Our genomic analysis of RAS isoform mutations in BRAF mutant CRCs showed enrichment in the non-V600 BRAF mutants, and in Figure 2F, we show that NRAS mutations are significantly enriched in BRAF Class 3 metastatic vs. primary CRC, whereas KRAS mutations are enriched in BRAF Class 3 primary CRC tumors (p = 0.0372 and p = 0.0109, respectively). The gene discussed is KRAS; the disease is colorectal carcinoma.